Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 plus toripalimab in c-Met-expressing advanced solid tumors
CTR20232828Phase 2Active
- Sponsor
- RemeGen
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of RC108 and toripalimab in Nonhematologic neoplasms, adenoid cystic carcinoma (ACC), gastrointestinal cancer and 7 more (3 arms), sponsored by RemeGen. Primary endpoints: Dose-limiting toxicity, Safety and tolerability and 3 more. Started Sep 2023; status: active.
02
Drugs
RC108toripalimab
03
Conditions
Nonhematologic neoplasmsadenoid cystic carcinoma (ACC)gastrointestinal cancerhead and neck squamous cell carcinoma (HNSCC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20232828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232828.